TUMOR, SOLID

This study tests whether a structured nutrition program can prevent malnutrition in children with solid tumors. About 400 children will receive personalized diet support from a team of experts. The goal is to improve weight, height, and overall health during treatment.

This early-phase study tests the safety of a drug called nab-sirolimus in adults with advanced solid tumors who also have moderate liver impairment. About 28 participants will receive the drug to see how their bodies process it and what side effects occur. The goal is to find the…

This early-phase study tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), in people with advanced solid tumors or lymphomas that have not responded to other treatments. The main goals are to find the safest dose and understan…

This program provides access to an experimental drug called AVM0703 for people with various solid tumors or blood cancers who have not responded to other treatments. It is available in the US upon a doctor's request. So far, 37 patients have received the drug, and side effects ha…

This early-stage study tests a personalized mRNA vaccine (RGL-270) designed to train the immune system to recognize and attack leftover cancer cells. It is for people with solid tumors who have a high risk of recurrence after surgery and standard treatments. The vaccine is given …

This early-phase study tests a new treatment using a patient's own immune cells, engineered to recognize and attack cancer cells with specific KRAS mutations. It is for people with advanced solid tumors who have no standard options left. The main goal is to check safety and find …

This early-stage trial tests a new treatment called LEU011 for people with solid tumors that have come back or not responded to standard therapies. LEU011 uses a patient's own immune cells, modified to target specific markers on tumor cells. The main goals are to check safety and…

This early-phase study tests a new treatment using a patient's own immune cells, engineered to attack cancer cells with specific KRAS mutations (G12V or G12D). It is for people with advanced solid tumors who have no standard treatment options left. The main goal is to check safet…

This study is for adults with advanced solid tumors that have stopped responding to standard treatments. It tests an experimental drug called INV-1120, given alone or together with the immunotherapy pembrolizumab. The main goals are to find the safest dose and to watch for side e…

This study tests a new drug called CNSI-Fe(II), which is injected directly into tumors. It uses iron to trigger a type of cell death called ferroptosis, aiming to shrink or control advanced solid tumors like lung, pancreas, and colorectal cancer. About 54 adults whose cancers hav…

This early-stage study tests two drugs, ulixertinib and palbociclib, together in people with advanced solid tumors, including pancreatic cancer and certain melanomas. The main goal is to find the safest dose and check for side effects. About 45 adults whose cancer has not respond…

This study tests if a safe dye called indocyanine green can make tumors glow during surgery, helping surgeons find and remove cancer that might otherwise be missed. About 500 adults with solid tumors will receive the dye before surgery, and special cameras will detect the glow. T…

This study is collecting blood samples from 1,500 cancer patients who are receiving FDA-approved immunotherapy. Researchers will analyze immune-related markers in the blood to see if they can predict whether the treatment will work. The goal is to better understand why some patie…